Drug Trial Radar · NCT02768363
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
187
Actual
Start
May 2016
Primary completion
Nov 2024
Study completion Dec 2026
Sponsor
- Lead sponsor
- Candel Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate cancer. CAN-2409 involves the use of aglatimagene besadenovec to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. CAN-2409 has been well tolerated in previous trials in patients with prostate cancer and other tumor types. Biochemical, pathologic and immune responses have been demonstrated in newly diagnosed and recurrent prostate cancer. The hypothesis is that CAN-2409 can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the CAN-2409 or control arm at a 2:1 ratio. Both arms receive standard of care active surveillance evaluations.
Conditions
- Prostate Cancer
Interventions
aglatimagene besadenovecBiological
Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
placeboBiological
Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
valacyclovirDrug
Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Baseline to study completion, approximately 5 years
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
Foothills Urology
Golden, Colorado
Jesse Brown VA Medical Center
Chicago, Illinois
The University of Chicago
Chicago, Illinois
Southeast Louisiana Veterans Health Care System
New Orleans, Louisiana
Walter Reed National Military Medical Center
Bethesda, Maryland
Kansas City VA Medical Center
Kansas City, Missouri
Sierra Nevada Health Care System VA
Reno, Nevada
Hackensack University Medical Center
Hackensack, New Jersey
Advanced Radiation Centers of New York (Integrated Medical Professionals)
North Hills, New York
Associated Medical Professionals of NY, PLLC
Syracuse, New York
Southwest Urology, Clinical Research Solutions
Middleburg Heights, Ohio
Oklahoma City VA Healthcare System
Oklahoma City, Oklahoma
VA Portland Health Care System
Portland, Oregon
Oregon Urology Insitute
Springfield, Oregon
Lancaster Urology
Lancaster, Pennsylvania
Allegheny Health Network-Triangle Urological Group
Pittsburgh, Pennsylvania
Ralph H. Johnson Veterans Affairs Medical Center
Charleston, South Carolina
San Antonio VA Healthcare System
San Antonio, Texas
Woodland Center
The Woodlands, Texas
Texas Urology Specialists
Tomball, Texas
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia
Salem VA Medical Center
Salem, Virginia
Instituto Nacional de Ciencias Medicas y Nutrición, Salvador Subirán
Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.